As the αDC1-DLK1 vaccination readily induced systemic CD8+ T cell responses against the DLK1162-169 peptide, reactivity against MC38 cells was only evident in animals also experiencing protection against MC38 tumor challenge in vivo (Figure 3E). The gene discussed is CD8A; the disease is neoplasm.